Endometriosis ~ Abdominal Pain ~ Endo ~ Scar Tissue ~ Adhesions ~ Infertility ~ Hysterectomy

Monday, May 16, 2011

Symptoms in teen years may foretell severe endometriosis

I have a 16 year old daughter.
 I suffer with deep infiltrating endo and I believe my mother and my grandmother may have suffered also. They both had hysterectomies at a young age. I had one at age 32.
 I am terrified for my daughter as I am sure all parents with Endo are. ~ Chef

Symptoms in teen years may foretell severe endometriosis
By Amy Norton

NEW YORK
Fri Nov 19, 2010 5:31pm EST




NEW YORK (Reuters Health) - In some teenage girls, very painful menstrual periods that interfere with daily life may signal an increased risk of developing the most extensive form of endometriosis, a preliminary study suggests.


In a study of 229 women undergoing surgery for endometriosis, French researchers found that those with the most extensive form -- known as deep infiltrating endometriosis (DIE) -- were more likely to have had particularly painful periods as teenagers.


As a group, they were four times as likely as women with non-DIE endometriosis to have used birth control pills to treat severe menstrual pain before the age of 18. And they were 70 percent more likely to say they'd missed school days because of menstrual symptoms.


The findings, published in the journal Fertility and Sterility, suggest that such problems in adolescence can sometimes predict a later diagnosis of DIE.

In endometriosis, pieces of the tissue that lines the uterus (the endometrium) also grow outside the organ -- often on the ovaries, the fallopian tubes or elsewhere in the pelvis. Like the endometrium, this misplaced tissue changes with each menstrual cycle, thickening and then breaking down and bleeding.




This leads to a buildup of adhesions, or scar tissue, outside the uterus, with symptoms including pelvic pain and heavy, painful menstrual periods. Some women also have difficulty becoming pregnant.



There are three forms of endometriosis: superficial endometriosis, ovarian endometriomas and DIE, with the latter being the most extensive. Women with DIE usually have adhesions in multiple areas of the pelvis, including the vagina, bladder, bowel and the ligaments attaching the uterus to the pelvis.



Endometriosis can be tricky to diagnose, and many girls and women go years before a diagnosis.



The condition may, for instance, be mistaken for other causes of pelvic pain, like ovarian cysts, pelvic inflammatory disease or, depending on the symptoms, irritable bowel syndrome. In addition, while a pelvic exam or ultrasound test are often used to help diagnose endometriosis, the only way to definitively diagnose it is through minimally invasive laparoscopic surgery to take a tissue sample.



Compared with the other forms of endometriosis, DIE appears to have a longer delay to diagnosis.



So for the new study, Dr. Charles Chapron and colleagues at Universite Paris Descartes tried to find out whether women undergoing surgery for endometriosis had any early symptom history that was associated with a greater likelihood of having DIE.



The study included 229 women who had surgery at a single medical center between 2004 and 2009; 43 percent had DIE, while the rest had the less-extensive forms of endometriosis. All of the women were interviewed about their symptom history; their average age at the time of surgery was 32.



Overall, 58 percent of women with DIE had ever been prescribed birth control pills to treat severe menstrual pain, versus 26 percent of women with non-DIE forms. Similarly, 21 percent of women with DIE had their first prescription before the age of 18, compared with 6 percent of those in the non-DIE group.



When it came to missed school days, 38 percent of DIE patients said they'd had absences due to menstrual symptoms, versus one-quarter of women in the non-DIE group.



Women with DIE were also more likely to report a family history of endometriosis; 13 percent did, compared with just under 5 percent of women with non-DIE endometriosis.



The study has a number of limitations, including the fact that it surveyed women at one time point and asked them to recall symptoms from adolescence. A study that followed young women over time to see whether symptoms predicted a later diagnosis of DIE would be more informative.



These findings now set the groundwork for such a long-term study, Chapron told Reuters Health in an email.



But the "crux of the issue," he noted, is whether diagnosing endometriosis earlier will eventually lead to fewer cases of DIE and less need for surgery.



"Today, there is no effective way to prevent the progression of endometriosis to its most severe stage, DIE," Chapron said.



And the current results, he noted, suggest that treating severe menstrual pain with birth control pills does not prevent progression to DIE, as a history of such treatment was linked to the condition. Chapron also pointed out, however, that this does not mean that birth control pills contributed to the development of DIE either.



Still, even though it is not clear whether progression to DIE can be prevented, an earlier diagnosis of endometriosis would at least allow girls and women to know the cause of their symptoms.



According to Chapron and his colleagues, girls and women with severe menstrual pain that does not respond to pain relievers like ibuprofen should see their doctors, and, if appropriate, be evaluated for endometriosis.



Besides painkillers and birth control pills, non-surgical treatments for endometriosis include several types of hormonal medications that inhibit the growth of the endometrial tissue.



SOURCE: link.reuters.com/xam46q Fertility and Sterility, online November 11, 2010

Monday, May 09, 2011

Smilage Dental: Dr Fred Attarzadeh of Smilage Dental Franklin and Framingham MA

Smilage Dental: Dr Fred Attarzadeh of Smilage Dental Franklin and Framingham MA

ENDURING Endometriosis

Painful disorder may increase risk of infertility

EILEEN CIPRIANI Times Leader Correspondent


It is among the top three causes of infertility and pelvic pain in women. There is a research center and a foundation in the United States, as well as an international society and yellow ribbon devoted to the disorder. According to the U.S. Department of Health and Human Services more than 5 million women in America alone have been diagnosed. Oscar Award-winning actress Susan Sarandon and “Top Chef” host Padma Lakshmi are among them. In March at the 3rd annual Blossom Ball fundraiser for research in New York, Sarandon and Lakshmi shared their first-hand experiences with the malady -- endometriosis.

Endometriosis is when endometrial cells that normally line the interior of the uterus relocate in other areas of the body. The cells usually become displaced in the pelvic area, but in extremely rare cases they can be found in other parts of the body, says Dr. Jennifer Sue Gell of Geisinger Health System’s Women’s Health Center. Gell is obstetrics-gynecology certified with a practicing specialty in reproductive endocrinology and fertility.


In endometriosis the displaced tissues acts as it normally would during the menstrual cycle. It thickens and bleeds, but because it is unable to exit the body it irritates surrounding tissue causing pain and eventually develops scar tissue and adhesions.

Click link to read the rest
http://www.timesleader.com/features/ENDURING_Endometriosis_05-02-2011.html

Sunday, April 24, 2011

Eggsploitation

04-06-11: Award-winning documentary, 'Eggsploitation', was shown at Boston College Law School. Risks of lupron, and the lack of data-tracking of women who undergo egg donation and IVF, were discussed. 'RESOLVE' (the organization that alleges to "educate, advocate, and support the infertile") had in attendance a Board Member who attempted to discredit 'Eggsploitation' as "biased" and 'not representative of the industry'. 'RESOLVE's' Board Member failed to inform the audience of 'RESOLVE's' conflicts of interest: RESOLVE has a history of receiving hundreds of thousands of dollars from the fertility drug manufacturers, fertility clinics, and fertility doctors.

From: http://www.lupronvictimshub.com/

Global Endometriosis Market to Reach $1.3 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

Monday, April 4, 2011

San Jose, CA (Vocus/PRWEB) April 04, 2011

Endometriosis is the most common health problem among women. As per the estimates of World Endometriosis Research Foundation, an estimated 170 million women suffer from endometriosis globally. Endometriosis-related healthcare costs and productivity losses exceed US$4,000 per patient annually. Annual direct and indirect endometriosis-related costs are estimated to cross US$20 to US$25 billion in the US over the coming years. The disease affects reproductive age women more compared to post-menopausal women. Endometriosis affects more than 90 million women of reproductive age globally. The disease represents one of the major causes of female infertility and constitutes for about 30% of infertility cases in women. More than 7.8 million women in the US suffer from endometriosis-related symptoms, which include chronic pelvic pain, dysmenorrhea, and infertility.

Gonadotropin-Releasing Hormone GnRH agonists, Progestins, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and contraceptives are the major therapeutic options available for the treatment of endometriosis. The present drugs are characterized by safety and efficacy concerns. Huge unmet medical need exists for novel medication with improved safety profile and minimal side effects. Lupron Depot from Abbott Laboratories, Depo-Provera and Synarel from Pfizer, are the major drugs approved for the treatment of endometriosis. Abbott's Lupron (Leuprolide) represents one of the leading drugs for the treatment of endometriosis.

The global endometriosis market is led by the US, as stated by a new market research report on Endometriosis. Europe represents the next largest region, while growth is expected to emanate mainly from the 'Rest of the world' market, which is expected to depict a compounded annualized growth of more than 6.0% during 2009-2017. The future looks promising for endometriosis, with increasing efforts being made in research, and novel treatment emerging in the field of surgical as well as pharmaceutical treatment. In addition, myths are being dispelled regarding the disease, and alternative methods are being readily accepted. Non-invasive diagnostics, including next-generation MRIs, are forecast to become major tools for the diagnosis of endometriosis, although laparoscopy, an invasive surgery, still remains the gold standard for performing disease diagnosis. Genetic and biomolecular diagnostic tests are also being trailed.

Drugs that are expected to drive future market growth include Abarelix, SERMs (Selective Estrogen Receptor Modulators), Extracellular Matrix Modulators, Terbutaline, and RU-486. Abarelix, for instance, is a GnRH antagonist, presently undergoing clinical trials in the US for its use in endometriosis. The emergence of certain other promising innovative drugs, including Repros Therapeutics' Proellex, Neurocrine's Elagolix, and Bayer HealthCare Pharmaceuticals' Visanne (Dienogest) is forecast to have a robust impact on the endometriosis market in future. Elagolix is the first oral non-peptide gonadotropin-releasing hormone (GnRH) antagonist. Meanwhile, Proellex acts by selectively blocking the activity of progesterone, and allows the secretions of tonic hormone by alleviating the negative side effects of GnRHa. Besides pipeline drugs, Angiogenesis therapy is forecast to be one of the key potential treatment options for endometriosis, whether used alone or as an adjunct therapy. Angiogenesis theory holds that endometriosis lesions could be destroyed by cutting off the blood supply.

Major players profiled in the report include Abbott Laboratories, AEterna Zentaris Inc., AstraZeneca Plc., Bayer HealthCare Pharmaceuticals Inc., Eli Lilly and Company, Meditrina Pharmaceuticals Inc., Neurocrine Biosciences Inc., Paladin Labs Inc., Pfizer Inc., Repros Therapeutics Inc., among others.

The research report titled "Endometriosis: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of endometriosis, current market trends, key growth drivers, the available treatment, overview of major drugs, insight into current leading and pipeline drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for Endometriosis treatment for the years 2009 through 2017 for the following geographic markets - US, Canada, Japan, Europe, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit - www.strategyr.com/Endometriosis_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
E-mail: press(at)StrategyR(dot)com
Web Site: www.StrategyR.com/
# # #


For the original version on PRWeb visit: www.prweb.com/releases/prwebendometriosis/laproscopy/prweb8257835.htm

http://sfgate.com/cgi-bin/article.cgi?f=/g/a/2011/04/04/prweb8257835.DTL


Thursday, April 07, 2011

Global Endometriosis Market to Reach $1.3 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.


Quote startEndometriosis: A Global Strategic Business ReportQuote end
GIA announces the release of a comprehensive global report on Endometriosis markets. The global market for endometriosis treatment is forecast to reach $1.31 billion by the year 2017. Major factors driving market growth include huge unmet need for novel and effective drugs in the market with improved safety profiles, increasing incidence rates of endometriosis due to environmental factors, rising awareness of the disease, and improved diagnosis. Drugs that are expected to drive future market growth include Abarelix, SERMs (Selective Estrogen Receptor Modulators), Extracellular Matrix Modulators, Terbutaline, and RU-486.

San Jose, CA (Vocus/PRWEB) April 04, 2011


Endometriosis is the most common health problem among women.
As per the estimates of World Endometriosis Research Foundation, an estimated 170 million women suffer from endometriosis globally. Endometriosis-related healthcare costs and productivity losses exceed US$4,000 per patient annually. Annual direct and indirect endometriosis-related costs are estimated to cross US$20 to US$25 billion in the US over the coming years. The disease affects reproductive age women more compared to post-menopausal women. Endometriosis affects more than 90 million women of reproductive age globally. The disease represents one of the major causes of female infertility and constitutes for about 30% of infertility cases in women. More than 7.8 million women in the US suffer from endometriosis-related symptoms, which include chronic pelvic pain, dysmenorrhea, and infertility.



Gonadotropin-Releasing Hormone GnRH agonists, Progestins, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and contraceptives are the major therapeutic options available for the treatment of endometriosis. The present drugs are characterized by safety and efficacy concerns. Huge unmet medical need exists for novel medication with improved safety profile and minimal side effects. Lupron Depot from Abbott Laboratories, Depo-Provera and Synarel from Pfizer, are the major drugs approved for the treatment of endometriosis. Abbott's Lupron (Leuprolide) represents one of the leading drugs for the treatment of endometriosis.



The global endometriosis market is led by the US, as stated by a new market research report on Endometriosis. Europe represents the next largest region, while growth is expected to emanate mainly from the ‘Rest of the world’ market, which is expected to depict a compounded annualized growth of more than 6.0% during 2009-2017. The future looks promising for endometriosis, with increasing efforts being made in research, and novel treatment emerging in the field of surgical as well as pharmaceutical treatment. In addition, myths are being dispelled regarding the disease, and alternative methods are being readily accepted. Non-invasive diagnostics, including next-generation MRIs, are forecast to become major tools for the diagnosis of endometriosis, although laparoscopy, an invasive surgery, still remains the gold standard for performing disease diagnosis. Genetic and biomolecular diagnostic tests are also being trailed.



Drugs that are expected to drive future market growth include Abarelix, SERMs (Selective Estrogen Receptor Modulators), Extracellular Matrix Modulators, Terbutaline, and RU-486. Abarelix, for instance, is a GnRH antagonist, presently undergoing clinical trials in the US for its use in endometriosis. The emergence of certain other promising innovative drugs, including Repros Therapeutics’ Proellex, Neurocrine’s Elagolix, and Bayer HealthCare Pharmaceuticals’ Visanne (Dienogest) is forecast to have a robust impact on the endometriosis market in future. Elagolix is the first oral non-peptide gonadotropin-releasing hormone (GnRH) antagonist. Meanwhile, Proellex acts by selectively blocking the activity of progesterone, and allows the secretions of tonic hormone by alleviating the negative side effects of GnRHa. Besides pipeline drugs, Angiogenesis therapy is forecast to be one of the key potential treatment options for endometriosis, whether used alone or as an adjunct therapy. Angiogenesis theory holds that endometriosis lesions could be destroyed by cutting off the blood supply.



Major players profiled in the report include Abbott Laboratories, AEterna Zentaris Inc., AstraZeneca Plc., Bayer HealthCare Pharmaceuticals Inc., Eli Lilly and Company, Meditrina Pharmaceuticals Inc., Neurocrine Biosciences Inc., Paladin Labs Inc., Pfizer Inc., Repros Therapeutics Inc., among others.



The research report titled “Endometriosis: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of endometriosis, current market trends, key growth drivers, the available treatment, overview of major drugs, insight into current leading and pipeline drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for Endometriosis treatment for the years 2009 through 2017 for the following geographic markets - US, Canada, Japan, Europe, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.



For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Endometriosis_Market_Report.asp



About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.



Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

E-mail: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/




Tuesday, March 29, 2011

If your doctor wants you to take Lupron, please watch this news clip first!

I took a 6 months course of Lupron when I was 32. All I can seem to remember about this is I wished  I had never done it. The side effects were awful. The pain of stage 4 endometriosis and their accompanying adhesions came right back.
I am now 49 with osteoperosis and almost an inch shorter than I was my whole adult life.
One time I presented at ER Mass General....and that witch sneered at me...."why aren't you taking lupron?"
I got off the table and just kept walking.....outta there!

Please....Lupron does not cure endometriosis.

Watch this investigative report before you decide to go this course.